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Novel Toll-like receptor-4 
antagonist (+)-naloxone protects 
mice from inflammation-induced 
preterm birth
Peck Yin Chin1, Camilla L. Dorian1, Mark R. Hutchinson2,3, David M. Olson4, Kenner C. Rice5, 
Lachlan M. Moldenhauer1 & Sarah A. Robertson1
Toll-like receptor 4 (TLR4) activation by bacterial infection, or by sterile inflammatory insult is a primary 
trigger of spontaneous preterm birth. Here we utilize mouse models to investigate the efficacy of a 
novel small molecule TLR4 antagonist, (+)-naloxone, the non-opioid isomer of the opioid receptor 
antagonist (−)-naloxone, in infection-associated preterm birth. Treatment with (+)-naloxone 
prevented preterm delivery and alleviated fetal demise in utero elicited by i.p. LPS administration 
in late gestation. A similar effect with protection from preterm birth and perinatal death, and 
partial correction of reduced birth weight and postnatal mortality, was conferred by (+)-naloxone 
administration after intrauterine administration of heat-killed E. coli. Local induction by E. coli of 
inflammatory cytokine genes Il1b, Il6, Tnf and Il10 in fetal membranes was suppressed by (+)-naloxone, 
and cytokine expression in the placenta, and uterine myometrium and decidua, was also attenuated. 
These data demonstrate that inhibition of TLR4 signaling with the novel TLR4 antagonist (+)-naloxone 
can suppress the inflammatory cascade of preterm parturition, to prevent preterm birth and perinatal 
death. Further studies are warranted to investigate the utility of small molecule inhibition of TLR-driven 
inflammation as a component of strategies for fetal protection and delaying preterm birth in the clinical 
setting.
Preterm birth, defined as birth at less than 37 weeks of gestation, accounts for 12% of all births worldwide,varying 
from 5–13% according to geographic region, race and socioeconomic status1,2. The cost to infant health is enor-
mous, particularly in undeveloped nations where the majority of spontaneous premature birth occurs3. Preterm 
birth is now the major cause of death in children under 5 years, accounting for 1.1 million deaths annually4, while 
surviving infants are at risk of a raft of developmental impairments with lifelong consequences5,6. Even late pre-
term infants born at 34–36 weeks gestation have substantial mortality and neonatal morbidity, and have elevated 
risk of long-term cardiovascular and metabolic conditions5,7. New interventions are urgently needed to tackle the 
underlying causes of preterm birth and stem the impact on fetal injury and ensuing child health8.
Preterm delivery (PTD) results when the labour and birth processes of normal parturition are prematurely acti-
vated. On-time, term labour involves events characteristic of a progressively accelerating inflammatory cascade9. 
Fetal signals trigger a surge in pro-inflammatory cytokines including Il1b, Il6 and Tnf within the fetal membranes, 
uterus and cervix and an accompanying influx of leukocytes into the gestational tissues10,11 amplifies the inflam-
matory sequalae to promote cervical ripening and rupture of the fetal membranes12,13. Cytokines interact with 
hormone changes to mediate induction of uterine activation genes (UAGs) and prostaglandin signaling, culmi-
nating in uterine contractions and expulsion of the fetus14,15.
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Precocious inflammation leading to preterm labor can be triggered by infection or by sterile pro-inflammatory 
insults, originating either within gestational tissues or systemically, from tissues distal to the placenta and fetus1,16. 
Detection of infection is mediated by sensing molecules known as Toll-like receptors (TLRs) that bind conserved 
molecular structures carried by microorganisms, known as pathogen-associated molecular patterns (PAMPs). 
TLRs also sense silent inflammation resulting from non-infectious insult, through ligation of endogenous agents 
released by injured tissue (damage-associated molecular patterns, DAMPs). The archetypal receptor in this detec-
tion system is TLR4, which is activated by the bacterial cell wall component lipopolysaccharide (LPS). TLR4 is 
extensively expressed throughout the female reproductive tract including the fetal membranes17,18 and placental 
trophoblasts19,20, as well as leukocytes, epithelial and mesenchymal cells in the cervix20 and uterus21. TLR-driven 
pathways are involved in normal on-time parturition, since mice with null mutation in Tlr4 or Tlr2 exhibit a delay 
in the timing of term labour22,23.
Infection-induced preterm labor can be modelled in mice by administration of LPS systemically or locally 
into the gestational tissues24–26, or delivery of killed E. coli into the uterine cavity or fetal membranes to mimic 
ascending infection and chorioamnionitis27,28. TLR4 is a key sensor for infection-induced preterm birth, since 
protection is afforded in mice by spontaneous mutation of Tlr4 in C3H/HeJ mice27,29,30, null mutation of Tlr4 in 
C57Bl/6 mice22,30, and genetic deficiency in the MyD88 and TRIF adaptor proteins required for TLR4 signaling28. 
TLR4 inhibitors including a lipid A mimetic and anti-TLR4 neutralising antibodies have previously shown prom-
ise in attenuating preterm birth in mouse infection models24,30, but neither of these are suitable for human clinical 
application.
These observations underpin our hypothesis that TLR4 inhibition with a novel TLR4 antagonist (+)-naloxone 
might comprise a useful strategy for targeted suppression of inflammation underlying preterm birth. 
(+)-Naloxone is a newly identified TLR4 antagonist that is the non-opioid isomer of the opioid receptor antago-
nist (−)-naloxone31, a well-described nonselective antagonist of the μ -opioid receptor commonly prescribed for 
opioid addiction, including in pregnant women and neonates32. (+ )-Naloxone binds MD2 to prevent LPS engage-
ment with TLR433 leading to diminished immune NFκ B activation and IL1B, IL6 and TNF synthesis34–36. In 
contrast to anti-TLR4 neutralizing antibodies24, (+ )-naloxone is a small molecule which can penetrate across the 
placenta37, with a pharmacokinetic profile affording it short systemic exposure or longer term delivery if required. 
(−)-Naloxone has anti-inflammatory activity and provides protection against sepsis in animal models38,39. 
(+)-Naloxone has similar properties but unlike (−)-naloxone, does not have opioid receptor-binding activity, and 
is a specific antagonist of TLR4 signaling31.
In view of the attractive pharmacological properties of (+ )-naloxone as a TLR4 antagonist and our previous 
observation that (+ )-naloxone can delay the timing of natural on-time parturition22, we sought to investigate the 
possible utility of (+ )-naloxone as a novel anti-inflammatory tocolytic agent. Here, we use two common mouse 
models of infection-induced preterm birth to show (+ )-naloxone protects against preterm delivery and alleviates 
in utero and postnatal loss induced by TLR-driven inflammation.
Results
(+)-Naloxone prevents LPS-induced preterm delivery (PTD). To investigate the effect of (+ )-nalox-
one in a TLR4-dependent model of infection-associated preterm birth, pregnant B6 dams were administered 
a low dose of LPS (0.5 μ g i.p.), selected after titration of LPS in pilot studies to elicit ~50% PTD, as previously 
described40,41. LPS was administered at gestation day (gd) 16.5 (~3 days before expected on-time birth at gd 19.5), 
followed immediately by the first of 4 doses of (+ )-naloxone or vehicle control at 12 h intervals until gd 18.0. Mice 
given LPS without (+ )-naloxone exhibited adverse outcomes, with a majority delivering dead pups (9/20) or live 
pups (2/20) prematurely within 36 h (and generally within 24 h) of LPS administration (Fig. 1A). Those few pups 
delivered alive before gd 18.0 failed to survive beyond 36 h. In all, PTD (defined as delivery of live or dead pups 
before gd 18.0) occurred in 55% (11/20) LPS-treated, but 0% (0/15) PBS-treated mice (p < 0.001) (Fig. 1B). In 
the 45% (9/20) LPS-treated dams remaining undelivered at gd 18.5, autopsy revealed a higher incidence of severe 
fetal growth restriction and fetal death (18.9%, 10/53) compared to PBS-treated controls (1/115, 0.8%, p = 0.023) 
(Fig. 1C,D). Taking into account pups delivered dead or identified as non-viable in utero, there was a 58% reduc-
tion in the mean number of viable fetuses per pregnant dam, compared with PBS-treated mice (Fig. 1E).
Treatment with (+ )-naloxone protected pregnancy from LPS challenge, completely abrogating PTD (0/14 
mice delivered before gd 18.0) (Fig. 1A,B). The low survival rate of fetuses in utero after LPS challenge was also 
reversed by (+ )-naloxone, such that the mean number of viable fetuses per dam was not less than the control 
PBS-treated group (Fig. 1C–E). Moreover, administration of (+ )-naloxone alone in the absence of LPS did not 
induce PTD (0/14 mice) or affect fetal survival rates (Fig. 1A–E).
When fetuses surviving in utero at gd 18.5 were analysed for effects of treatments on fetal and placental 
weight, mixed model ANOVA showed that LPS reduced fetal weight (p = 0.033) (Fig. 2A) and elevated placental 
weight (p = 0.019) (Fig. 2B), causing a substantial reduction in fetal:placental weight ratio (p = 0.001) (Fig. 2C), 
a parameter indicative of placental functional efficiency. Conversely (+ )-naloxone exerted a positive impact on 
fetal weight (p = 0.045), and did not affect placental weight or fetal:placental weight ratio. Post-hoc analysis to 
compare individual treatment groups demonstrated a 15.2% reduction in fetal:placental weight ratio after LPS 
treatment compared to PBS control (p = 0.036) (Fig. 2C), but (+ )-naloxone treatment was not able to correct this.
These data indicate that (+ )-naloxone can effectively inhibit TLR4 signaling to prevent PTD and rescue fetal 
loss elicited by LPS administration in late gestation. However, fetuses that survive LPS challenge in utero exhib-
ited altered placental efficiency indicated by reduced fetal:placental weight ratio, regardless of (+ )-naloxone 
treatment.
(+)-Naloxone prevents heat-killed E. coli-induced preterm delivery. Given the ability of 
(+ )-naloxone to prevent LPS-induced PTD, we next investigated whether (+ )-naloxone can also prevent PTD 
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Figure 1. (+)-Naloxone prevents LPS-induced PTD and fetal loss. Pregnant B6 mice were administered 
LPS or PBS i.p. on gd 16.5, followed by (+ )-naloxone or PBS i.p. on gd 16.5, 17.0, 17.5 and 18.0, then observed 
for PTD (delivered gd < 18.0) and autopsied at gd 18.5. (A) Dam outcomes at gd 18.5, classified as (i) pregnant 
(>1 live fetus); (ii) delivered early (gd 18.0–18.5); delivered preterm (gd < 18.0; >1 live pup), or (iv) delivered 
preterm, all pups dead. (B) The percentage of pregnant dams exhibiting PTD. (C) Fetuses and placentae 
dissected from a representative dam in each treatment group. Pups marked ‘*’ are judged non-viable.  
(D) Fetal outcomes at gd 18.5, classified as (i) resorbed; (ii) viable, in utero; (iii) viable, delivered preterm;  
(iv) non-viable, in utero, or (v) dead, delivered preterm. All pups born alive before gd 18.0 were dead within 
36 h. (E) The number of viable pups per dam. Data in (A,B,D) are percentage analyzed by χ 2 test. Data in  
(E) are mean ± SEM analysed by two-way ANOVA. Number of pregnant dams per group is shown in 
parentheses. a,b,cDifferent letters indicate differences between groups, p < 0.05.
www.nature.com/scientificreports/
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induced by intact bacteria, which elicit PTD by ligation of multiple TLRs including TLR4 and TLR242,43. In this 
experiment, we used a proven model of chorioamnionitis-induced PTD wherein heat-killed E. coli are surgically 
Figure 2. Effects of LPS and (+)-naloxone on fetal and placental weight. Pregnant B6 mice were 
administered LPS or PBS i.p. on gd 16.5, followed by (+ )-naloxone or PBS i.p. on gd 16.5, 17.0, 17.5 and 
18.0, then fetal weight, placental weight and fetal:placental weight ratio were measured at gd 18.5. (A) Fetal 
weight; (B) placental weight, and (C) fetal:placental weight ratio for surviving fetuses. Data are estimated 
marginal mean ± SEM, analyzed by Mixed Model Linear Repeated Measures ANOVA and post-hoc LSD t-test, 
with mother as the subject, adjusted for litter size. a,b,cDifferent letters indicate differences between groups, 
p < 0.05. *Significant effect of LPS, independent of (+ )-naloxone, p < 0.05. #Significant effect of (+ )-naloxone, 
independent of LPS, p < 0.05. Number of pregnant dams per group is shown in parentheses.
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instilled into the uterine cavity between gestation sacs27,28. The dose of heat-killed E. coli was selected to elicit 
~50% PTD after titration of E. coli in pilot studies. After E. coli administration on gd 16.5, mice were monitored 
for time of delivery and the survival of pups. Instillation of killed E. coli into the uterus on gd 16.5 caused PTD in 
70% (7/10) of treated mice (Fig. 3A), with an associated 36 h average reduction in gestation length (Fig. 3B) and 
66% reduction in viable litter size at birth (Fig. 3C). The timing of birth and live birth rate were substantially res-
cued by (+ )-naloxone treatment, with none of 10 mice delivering before gd 18.0, a comparable gestation length, 
and no change in mean number of viable pups born compared to PBS control (Fig. 3A–C). Again, (+ )-naloxone 
alone had no impact on timing of birth or litter size (Fig. 3A–C).
When surviving delivered pups were analysed for effects of treatments at 12–24 h after birth, mixed 
model ANOVA showed E. coli administration had a strong negative impact on pup birth weight (p < 0.001). 
(+ )-Naloxone did not affect birth weight independently, but a significant interaction with E. coli was present 
(p < 0.001). Post-hoc analysis revealed that co-administration of (+ )-naloxone alleviated the reduction in birth 
weight caused by E. coli treatment, such that the pups born after exposure in utero to both (+ )-naloxone and 
E. coli were not different in weight to pups of PBS-treated control dams (Fig. 3D).
The majority of pups born small were lost in the post-natal and pre-weaning period, with only 13% of pups 
born alive from dams administered E. coli surviving to 3 weeks of age, compared to 90% and 88% respectively of 
pups from dams given PBS or (+ )-naloxone controls. Co-administration of (+ )-naloxone rescued the majority 
of pups with 56% surviving to 3 weeks of age (Fig. 3E), at which time their growth was comparable to those of the 
control groups (Fig. 3F).
This experiment demonstrates the utility of the TLR4 antagonist (+ )-naloxone in preventing prematurity and 
perinatal death, and alleviating fetal and postnatal growth impairment, in a physiologically relevant model of 
preterm birth and in utero inflammation.
(+)-Naloxone abrogates fetal and uterine cytokine expression induced by heat-killed E. coli. 
E. coli-induced preterm birth is elicited when ligation of TLRs activates an inflammatory cascade, initiated when 
activation of NFκ B triggers expression of pro-inflammatory cytokines Il1b, Il6 and Tnf in the fetal membranes 
and other gestational tissues22,28,44. In turn, cytokines induce uterine activation genes to cause prostaglandin 
synthesis and signaling, cervical ripening and uterine contractions15,45. To examine the mechanisms underlying 
the protective action of (+ )-naloxone, we evaluated whether pro-inflammatory cytokines induced by intrauter-
ine instillation of E. coli are influenced by (+ )-naloxone administration. The placenta and fetal membranes, as 
well as maternal decidua and myometrium were collected from the two fetal units located immediately adjacent 
to the injection site, 4 h after E. coli administration with or without (+ )-naloxone treatment, as before. In the 
fetal membranes and placenta, the sites of earliest response to TLR ligation to trigger the labor cascade22, E. coli 
induced a 9.1-fold and 2.1-fold increase in Il1a expression, a 62-fold and 6.3-fold increase in Il1b, a 33-fold and 
3.3-fold increase in Il6, a 131-fold and 3.7-fold increase in Tnf, and 95-fold and 4.3-fold increase in Il10, com-
pared to tissues from control mice given PBS (Fig. 4A–J). Administration of (+ )-naloxone substantially reduced 
E. coli-driven cytokine expression particularly in fetal membranes, meeting statistical significance for Il1b, Il6, Tnf 
and Il10, which were reduced by 78%, 84%, 66% and 73% respectively (Fig. 4G–J).
In the maternal tissues of the uterine decidua and myometrium, which are more spatially distant from the 
injection site, E. coli elicited increases in some of the same pro-inflammatory cytokines, although to a lesser 
extent than in fetal tissues (Fig. 5A–L). (+ )-Naloxone given with E. coli challenge reduced decidual expression 
of Il1a by 62% (Fig. 5G), and reduced Tnf in both the myometrium and decidua by 43% and 45% respectively 
(Fig. 5D–J). Most uterine activation genes (Gja1, Oxtr, Ptger4, Ptgfr and Ptgs1; data not shown) were not elevated 
by E. coli treatment, likely because of the short 4 h time window between treatment and tissue analysis. However, 
Ptgs2 encoding prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2, Cox2) was increased in response to 
E. coli challenge in both the myometrium (12.1-fold, Fig. 5F) and decidua (7.0-fold, Fig. 5L) compared to control. 
A trend towards decreased Ptgs2 after (+ )-naloxone treatment in E. coli challenged mice did not reach statistical 
significance in either tissue (Fig. 5F,L). (+ )-Naloxone administered without E. coli had no impact on gene expres-
sion in any of the fetal or maternal tissues (Figs 4 and 5).
These data show that the surge in pro-inflammatory cytokines released from fetal tissues contacting killed 
E. coli to trigger PTD, is suppressed by (+ )-naloxone. This is consistent with an action of (+ )-naloxone in pre-
venting TLR4 ligation to trigger initiation of the inflammatory cascade that ultimately leads to preterm birth.
Discussion
Normal on-time delivery is an inflammatory process that involves release of endogenous TLR ligands from the 
maturing fetus to ligate TLRs in fetal membranes and placental tissue22,23,46. Preterm delivery results when infec-
tion and/or sterile inflammatory agents cause pathogen-derived or endogenous TLR ligands to prematurely 
activate the TLR-induced inflammatory cascade8,26. Here we demonstrate that administration of a novel small 
molecule TLR4 antagonist (+ )-naloxone is an effective treatment to suppress PTD and associated perinatal death 
induced in mice by systemic LPS or intrauterine administration of heat-killed E. coli. Gene expression analysis 
reveals that (+ )-naloxone treatment inhibits E. coli-induced progression of the labor cascade by inhibiting induc-
tion in fetal membranes of pro-inflammatory cytokines Il1a, Il1b, Il6 and Tnf, which are identified as responsi-
ble for the amplification of inflammation and eventual maturation of the myometrium to overcome quiescence, 
induce cervical ripening, activate uterine contraction and expel the fetus41,47. All dams that received four doses of 
(+ )-naloxone at 12 h intervals, effectively encompassing the window between inflammatory challenge and earliest 
gestational age compatible with post-delivery survival in mice, delivered on time with the expected number of 
pups. The majority of pups survived the perinatal period and developed normally to 3 weeks of age. This demon-
strates that (+ )-naloxone protection of fetuses from TLR4-driven inflammation in late gestation is consistent with 
normal birth, postnatal survival and development of offspring at least to weaning age.
www.nature.com/scientificreports/
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Exposure to TLR4-induced inflammation impacted fetal growth in late gestation, in association with evi-
dence of reduced placental transport function, as described in previous studies40,48. Although no protective effect 
on mean fetal weight in viable fetuses was discernible at gd 18.5, fetuses at this time had been exposed to a 
Figure 3. (+)-Naloxone prevents E. coli-induced PTD and fetal loss. Pregnant B6 mice were administered 
intrauterine heat-killed E. coli or PBS on gd 16.5, followed by (+ )-naloxone or PBS i.p. on gd 16.5, 17.0, 17.5 and 
18.0, then observed for PTD and allowed to progress to birth. (A) The percentage of pregnant dams exhibiting 
PTD, analyzed by χ 2 test. (B) The gestation length, (C) number of viable pups born per dam, (D) pup weight 
at 24 h, (E) pup survival to 3 weeks and (F) weight of surviving pups at 3 weeks. (B,C,E) Data are mean ± SEM 
analyzed by two-way ANOVA, and (D,F) data are estimated marginal mean ± SEM, analysed by Mixed Model 
Linear Repeated Measures ANOVA and post-hoc LSD t-test, with mother as the subject. a,b,cDifferent letters 
indicate differences between groups, p < 0.05. *Significant effect of E. coli, independently of (+ )-naloxone, 
p < 0.001. Number of pregnant dams per group is shown in parentheses.
www.nature.com/scientificreports/
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Figure 4. (+)-Naloxone suppresses E. coli–induced pro-inflammatory cytokine expression in placenta 
and fetal membranes. Pregnant B6 mice were administered intrauterine heat-killed E. coli or PBS on gd 16.5, 
followed by (+ )-naloxone or PBS i.p., and 4 hours later, placenta and fetal membranes were recovered from the 
two adjacent implantation sites. Relative expression of Il1a (A,F), Il1b (B,G), Il6 (C,H), Tnf (D,I) and Il10 (E,J) 
mRNAs were determined in placenta (A–E) and fetal membranes (F–J) by qPCR and normalised to Actb. Data 
are mean ± SEM relative gene expression of n = 12 tissues from n = 6 dams/group and were analysed by one-
way ANOVA and post-hoc Sidak t-test. a,b,cDifferent letters indicate differences between groups, p < 0.05.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:36112 | DOI: 10.1038/srep36112
Figure 5. (+)-Naloxone suppresses E. coli–induced pro-inflammatory cytokine expression in uterine 
decidua and myometrium. Pregnant B6 mice were administered intrauterine heat-killed E. coli or PBS on gd 
16.5, followed by (+ )-naloxone or PBS i.p., and 4 hours later, uterine decidua and myometrium were recovered 
from the two adjacent implantation sites. Relative expression of Il1a (A,G), Il1b (B,H), Il6 (C,I), Tnf (D,J), 
Il10 (E,K) and Ptgs2 (F,L) mRNAs were determined in placenta (A–F) and fetal membranes (G–L) by qPCR 
and normalised to Actb. Data are mean  ± SEM relative gene expression of n = 12 tissues from ne = 6 dams/
group and were analysed by one-way ANOVA and post-hoc Sidak t-test. a,b,cDifferent letters indicate differences 
between groups, p < 0.05.
www.nature.com/scientificreports/
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pro-inflammatory environment for just 48 h, and effects on growth were less evident than in the E. coli model 
where birth weights were examined. Reduced birth weight was evident in pups exposed in utero to E. coli, and this 
was at least partly reversed by (+ )-naloxone treatment.
TLR4 is present in many compartments of the gestational tissues and reproductive tract and is well-positioned 
as a key sensing system and rapid first-line response to ascending or systemic bacterial infection. Fetal membrane 
TLR4 expression appears of paramount importance as the membranes comprise the site of earliest response to 
endogenous TLR ligation to trigger term labor22. The highest fold-change expression in inflammatory cytokines 
induced by E. coli was seen in this tissue as opposed to placental or uterine tissues, and additionally cytokine 
suppression by (+ )-naloxone was most profound in this compartment.
Mouse models of preterm birth often report heterogeneous effects amongst dams including preterm delivery 
of dead and live pups, and/or fetal injury or death in utero without delivery48,49. In the current study most dams 
delivered dead pups within 36 h of LPS or E. coli administration. With this outcome it is not obvious whether 
fetal death occurs in utero or in the perinatal phase, and thus whether death is the cause or consequence of early 
delivery. However, the observation of fetal death in utero in several dams, 48 h after LPS administration at gd 
18.5, is consistent with the view that fetal injury and death can occur in situ after inflammatory challenge, inde-
pendently of early delivery. Likewise, birth of live pups in a small proportion of preterm deliveries suggests fetal 
death is not essential for premature activation of the maternal parturition response. Consistent with previous 
reports48, we found that live pups born before gd 18.0 died soon after birth, presumably due to a combination 
of developmental immaturity and inflammatory injury inflicted in utero. These observations are consistent with 
interacting but distinct causal pathways underpinning the effects of inflammatory triggers on fetal and maternal 
tissue compartments.
Suppression of TLR4-induced pro-inflammatory cytokine expression in gestational tissues is inferred to be the 
key mechanism underlying the failure of bacterial agent-induced inflammation to progress to premature labor 
in mice given (+ )-naloxone, in turn protecting mice from subsequent late gestation or perinatal death of fetuses. 
Our data using both LPS and heat-killed E. coli to induce preterm delivery are consistent with previous studies 
employing these models27,28, where elevated IL1B, IL6 and TNF signaling are implicated in progressing both the 
uterine maturation and injury to fetal tissues that ultimately results in preterm birth and fetal death respectively.
Administration of (+ )-naloxone to mice given E. coli substantially suppressed cytokine expression, particu-
larly in fetal membranes and variably in placenta, the tissues most proximal to E. coli deposition between fetal 
sacs. This demonstrates that inhibition of TLR4 signaling in these tissues can prevent the progression of the 
inflammatory cascade that culminates in preterm birth and fetal death. It is notable that (+ )-naloxone is effi-
cacious despite the fact that E. coli activates inflammation by activation of TLRs in addition to TLR4, including 
TLR242,43. Different TLRs can trigger different cellular responses in gestational tissues, for example in placental 
trophoblasts where TLR4 ligation induces cytokine expression whereas TLR2 predominantly leads to apopto-
sis19. This presumably affects placental function and fetal growth, thus explaining why despite robust protection 
from preterm birth and perinatal death, (+ )-naloxone was only partially effective in mitigating fetal growth 
impairment and protecting growth restricted pups from death in the postnatal phase following E. coli treatment 
in utero. Although (+ )-naloxone is a small molecule that is able to penetrate the placental barrier37, it is possible 
that (+)-naloxone accesses the maternal and fetal compartments to differing extents, perhaps reaching higher 
and more effective concentrations in maternal tissues than in fetal tissues. Further experiments are required to 
investigate this, as well as to evaluate how (+ )-naloxone affects cervical ripening, another important aspect of the 
parturition cascade.
In addition to pro-inflammatory genes, we examined effects of E. coli and (+ )-naloxone on expression of 
UAGs. Induction of UAGs is secondary to hormone changes and pro-inflammatory cytokine upregulation15 so 
given the short time frame of the gene expression experiment, it is unsurprising that most UAGs were not elevated 
4 h following E. coli administration. Expression of Ptgs2 which controls PGE2 synthesis was elevated 4 h after 
E. coli administration, and a trend to suppression in its expression was evident with (+ )-naloxone treatment. 
(+ )-Naloxone has previously been shown to reduce LPS-induced TLR4-mediated Ptgs2 and PGE2 synthesis in 
mouse macrophages36. PGE2 is a key factor in the prostaglandin signaling pathway required for cervical ripening 
and parturition50. Sustained delivery of (+ )-naloxone beyond a single dose may be required to achieve greater 
Ptgs2 suppression.
Previous studies support the notion of targeting TLR4 to prevent infection-associated preterm birth. Blockade 
of TLR4 signaling with anti-TLR4 monoclonal antibody reduces leukocyte activation and the incidence of pre-
term labor induced by LPS24. In mice given Fusobacterium nucleatum, a gram negative bacteria associated with 
preterm birth and premature rupture of membranes in women51, administration of a TLR4 antagonist lipid A 
mimetic CXR-526 acted to reduce fetal loss30. CXR-526 did not suppress bacterial colonization of the placenta, 
but did reduce the extent of necrosis within placental tissue30. The authors concluded that decreased placen-
tal necrosis might reflect TLR4 antagonist-mediated suppression of pro-inflammatory cytokine expression, as 
reported previously for CXR-526 in a mouse model of inflammatory bowel disease52, but cytokines were not 
directly investigated in that study.
Other studies identify downstream agents of TLR4-driven inflammation as additional effective targets 
for inhibiting infection-induced preterm birth53. Experiments in null mutant mice implicate IL1 and IL6, 
cytokines induced by TLR4 activation of NFκ B, in amplifying and accelerating the birth cascade41,47, while 
anti-inflammatory IL10 suppresses IL1 and IL6 production and protects against LPS-induced preterm birth48,54. 
As well as cytokines, immune regulators that attenuate TLR-mediated inflammation can impact susceptibility 
to LPS-induced preterm birth. For example, the cannabinoid receptor Cnr2 modulates dendritic cell produc-
tion of IL10 and IL6, such that mice genetically deficient in Cnr2 are resistant to LPS-induced preterm birth55. 
Prostaglandins synthesized after Ptgs2 induction by LPS administration contribute to cervical ripening and 
other endpoints of parturition, and suppression of Ptgs2 with specific inhibitors can modulate LPS-induced PTD 
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rate56. Pretreatment with rosiglitazone, which promotes placental synthesis of peroxisome proliferator-activated 
receptor-γ (PPARγ ) similarly attenuates responsiveness to LPS-induced PTD, in association with suppressed NFκ 
B signaling and reduced synthesis of TNF, IL1, IL6 and other pro-inflammatory chemokines57. Thus the current 
study adds to considerable evidence that TLR-driven inflammatory signaling can be attenuated to effectively 
reduce susceptibility to preterm birth.
TLR4 is an attractive drug target in preterm birth because of its role at the apex of the inflammatory pathway. 
(+ )-Naloxone and related drug compounds have potential benefits over neutralising antibodies and other TLR4 
antagonists. (+ )-Naloxone potently blocks LPS-induced TLR4-mediated signaling in a variety of non-pregnancy 
models, suppressing NFκ B activation and inhibiting TNF and IL1B induction in immune cells34,35. As well as 
capacity to access and cross the placental barrier37, the established safety profile of closely related (−)-naloxone 
in pregnancy and infants is encouraging. In humans, (−)-naloxone is approved for use in pregnancy and no 
negative neonatal outcomes are reported58,59. Given the lack of opioid receptor activity of (+)-naloxone owing 
to the stereo-selectivity of opioid receptors33, (+ )-naloxone has distinct advantages over the currently available 
(−)-naloxone by virtue of its inability to alter endogenous opioid signaling, which in a clinical setting would 
afford freedom to employ exogenous opioids for maternal pain relief in labor.
Together, these results indicate that (+ )-naloxone is a useful experimental drug for investigating the utility of 
small molecule TLR inhibitors as pharmacological agents that might be administered in association with antibi-
otics to contain infection and suppress progression to preterm birth53. While clearly there are major challenges 
to consider in extrapolating this work to clinical application, we speculate that such TLR4 inhibitors may have 
particular value as prophylactic agents in threatened preterm labour where increased TLR4 expression disposes 
to elevated susceptibility, even in the absence of infection60,61, or when TLR4 SNPs associated with an increased 
risk of PTD and premature rupture of membranes are identified62,63. A likely advantage over current tocolytic 
agents is that TLR4 inhibitors act upstream of the pro-inflammatory cascade, overcoming the limitation of agents 
such as prostaglandin inhibitors which suppress uterine contractility, the final phase of labour, without impacting 
upstream pro-inflammatory activity45,64.
A key consideration is the impact on the neonate of in utero exposure to TLR4 inhibitors, and their effect on 
fetal capacity to withstand intrauterine inflammation, which is present to some extent in the majority of human 
preterm deliveries8. Sequalae of in utero inflammatory insult include fetal and newborn brain white matter disease, 
cerebral palsy, necrotizing enterocolitis, and chronic lung disease8, causing neurodevelopmental disability and 
a range of recurrent health problems in childhood5. Inflammation can provoke fetal brain injury even when 
inflammation is insufficient to activate parturition49, indicating the risk of sustained exposure to inflammatory 
mediators in utero. Clearly, clinical progression of this work requires extensive investigation of the benefits and 
risks of pharmacological delay of preterm birth for offspring, particularly effects on neurodevelopment, to ensure 
any treatment interventions adequately protect the fetus from inflammatory injury in utero.
Materials and Methods
Mice. C57Bl/6 (B6) mice were obtained from Laboratory Animal Services, University of Adelaide and main-
tained in the specific pathogen-free University of Adelaide Medical School Animal House with a 12:12 h light-
dark cycle. Food and water were provided ad libitum. Animals were utilized in accordance with the NHMRC 
Australian Code of Practice for the care and use of animals for scientific purposes. All experimental protocols 
were approved by the University of Adelaide Animal Ethics Committee, using methods in accordance with the 
relevant guidelines and regulations.
One to three virgin female mice of 8–12 weeks of age were housed with a proven fertile B6 male and checked 
daily between 0800–1000 h for vaginal plugs, as evidence of mating. The morning of vaginal plug detection was 
designated gestational day (gd) 0.5. Females were removed from the male and housed individually.
Treatments and pregnancy outcomes, i.p. LPS model. Pregnant mice were administered lipopoly-
saccharide (LPS, 0.5 μ g; S. typhimurium; Sigma-Aldrich, St. Louis, MO, USA) in 200 μ l PBS i.p., or PBS control, 
at 1100 h on gd 16.5; a protocol shown previously to induce PTD in ~50% of B6 mice40 41. Mice were immediately 
administered (+ )-naloxone (60 mg/kg) in 100 μ l PBS + 0.1% BSA i.p., or vehicle control, within 5 min of LPS 
injection on gd 16.5, plus a further 3 equivalent doses at 12 h intervals on gd 17.0, 17.5 and 18.0.
Mice were monitored for evidence of delivery at 12 h intervals after the gd 16.5 treatment until gd 18.5. Vaginal 
bleeding or the presence of intact or partial fetal tissue, viable or non-viable pups in the cage was noted. Delivery 
of live or dead pups before gd 18.0 was designated PTD. At gd 18.5 all mice were killed by cervical dislocation 
and the intact uterus was removed and analysed as described40. At autopsy, maternal outcomes were classified as 
pregnant with viable fetuses (at least one normal fetus of > 800 mg); delivered early (>1 live pup born gd 18.0–
18.5), delivered preterm with live pups (>1 live pup born gd 16.5–18.0), or delivered preterm with dead pups (gd 
16.5–18.0, all pups dead). The % maternal outcome in each category for each treatment group was calculated as 
[number]/[total pregnant mice] × 100. Fetal outcomes were classified as viable in utero (normal fetus > 800 mg), 
non-viable in utero (fetus hemorrhagic, anemic, malformed, or severely growth retarded < 600 mg), delivered 
preterm, viable (fresh implantation scar, viable pup), delivered preterm, dead (fresh implantation scar, no via-
ble pup) or resorbed (hemorrhagic mass < 5 mm in diameter). The % fetal outcome in each category for each 
treatment group was calculated as [number]/[total implantation site] × 100. When viable fetuses were present, 
each fetus was dissected from the amniotic sac and umbilical cord, fetuses and placentae were weighed, and the 
fetal:placental weight ratio calculated.
Treatment and pregnancy outcomes, in utero E. coli model. E. coli (serotype o55:K59(B5):H-) from 
American Type Culture Collection No. 12014 was grown overnight in 1000 ml Luria broth (LB) with shaking at 
37 °C. Bacteria were washed by centrifugation in sterile PBS and killed at 100 °C for 20 min, verified by lack of 
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growth overnight on LB agar plates. Prior to heat treatment, aliquots of live bacteria were plated on LB agar plates 
at 1 in 10 serial dilutions to quantify colony forming units (cfu). The heat-killed E. coli suspension was stored in 
aliquots of 1 × 1011 cfu/ml at − 80 °C until use.
Pregnant mice were anesthetised with avertin at 1100 h on gd 16.5 and a 1.5 cm midline incision was made on 
the lower abdomen. Heat-killed E. coli (5 × 1010 cfu in 100 μ l) or PBS was injected into the midsection of the left 
uterine horn at a site between two adjacent fetuses, in a treatment shown to elicit at least 50% PTD, as described28. 
The abdominal incision was closed in two layers, using sutures through the peritoneal wall and the skin. Mice 
were administered (+ )-naloxone or vehicle as above immediately after wound closure, plus a further 3 doses at 
12 h intervals as above, and allowed to recover. Females were monitored until birth for the time of parturition 
and the number of viable pups born, as above. Pups were weighed at 12–24 h post-delivery, at 8 days of age and 
at weaning.
Cytokine and uterine activation gene expression. A second cohort of pregnant females was adminis-
tered E. coli or vehicle, as above. The site of injection was marked by a single interrupted suture through the uterus 
layer prior to injection. Mice were killed by cervical dislocation 4 h post-surgery and the intact uterus of each 
female was removed. The two implantation sites adjacent to the injection site were each dissected into uterine 
myometrium (between implantation sites), entire uterine decidua (at placental attachment site), placenta and fetal 
membranes, and snap-frozen in liquid N2, then stored at − 80 °C.
Tissues were homogenised using ceramic beads (Mo Bio) in Trizol (Ambion RNA, Carlsbad CA) and RNA 
was precipitated using isopropanol and ethanol, then DNAse-treated using Ambion DNA-free™ Kit according to 
the manufacturer’s instructions. RNA purity and concentration were determined by A260 and A280 (NanoDrop, 
Wilmington, DE) and RNA integrity was verified by denaturing agarose electrophoresis. First strand cDNA 
was reverse-transcribed from 2 μ g extracted RNA with Superscript III (Invitrogen Life Technologies, Carlsbad, 
CA) according to the manufacturer’s instructions, with 200 ng random sequence oligohexamers (Geneworks, 
Adelaide, Australia) and 500 ng oligo dT18 (Proligo, Lismore, Australia) at 52 °C for 1 h. Each reaction contained 
2 μ L of cDNA (10 ng/μ L) and 18 μ L of master mix consisting of Power SYBR® Green PCR Master Mix (Life 
Technologies, Carlsbad, CA), 0.5–1 μ M of 5′ and 3′ primers (listed in Supplementary Table S1) and RNase free 
water. PCR reactions were 10 min at 95 °C followed by 40 cycles of 95 °C for 15 sec and 60 °C for 45 sec, using 
a Rotorgene 6000 (Corbett Life Sciences, Sydney, Australia). PCR product integrity was confirmed by High 
Resolution Melt analysis. Data were normalized to β -actin mRNA expression and expressed as Δ Δ CT using the 
formula mRNA level = Log2 - (CtBactin − Cttarget gene).
Statistical analysis. All statistical analysis was conducted using SPSS for Windows, version 20.0 software 
(SPSS Inc, Chicago, IL). Data were tested for normality using a Shapiro–Wilk test. ANOVA and post hoc T-tests 
were used when data were normally distributed. Kruskal-Wallis and Mann-Whitney U-test were used when data 
were not normally distributed. Pregnancy outcome and fetal outcome data expressed as percentage were com-
pared by χ 2 analysis. Gestation length and viable litter size data expressed as mean ± standard error of the mean 
(SEM) are analyzed by two-way ANOVA and post-hoc LSD test. Fetal weight, placental weight, fetal:placental 
weight ratio, growth trajectory and body composition data is expressed as estimated marginal means ± SEM 
and analysed by Mixed Model Linear Repeated Measures ANOVA and post-hoc LSD t-test, with mother as sub-
ject. Growth curve data was also analysed by Area Under the Curve (AUC) analysis in R studio. qPCR data 
are mean ± SEM analyzed by one-way ANOVA and post-hoc Sidak t-test (to adjust for multiple comparisons). 
Differences between groups were considered significant when of p < 0.05.
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